Radiotherapy given within 6 months of radical prostatectomy reduces cancer-specific mortality in men with highly aggressive disease.
Prostate cancer patients undergoing radical prostatectomy increased by double digits while those undergoing brachytherapy decreased.
High rates of preserved sexual function with combination beam plus brachytherapy.
Utilization rates jumped by double digits across prostate cancer risk groups from 2004 to 2011.
Men with male pattern baldness may face a higher risk of aggressive prostate cancer.
This benefit is not seen in patients who undergo radical prostatectomy, according to an updated meta-analysis.
Black prostate cancer patients more likely to develop aggressive disease earlier than white patients.
Low-dose aspirin decreased the likelihood of acute genitourinary toxicity in prostate cancer by 27%.
Enzalutamide and abiraterone may not benefit men with metastatic castration-resistant prostate cancer who have AR-V7 in circulating tumor cells.
However, they are more likely to die from causes other than prostate cancer than men with normal metabolic levels.
The drug is now also approved for use in chemotherapy-naïve men with metastatic castration-resistant prostate cancer.
Study finds a 15-year cancer-specific survival rate of 94%; hormone therapy for more than 6 months decreases all-cause survival.
Detection of AR-V7 in circulating tumor cells linked to enzalutamide and abiraterone resistance.
New study highlights the importance of digital rectal examinations in PCa patients with normal-range PSA at diagnosis.
Findings seen in economically disadvantaged men with newly diagnosed prostate cancer.
Studies show integrated program effective for depression in patients with cancer.
Risk is greater in patients managed with watchful waiting than in those who undergo radical treatment.
In a study, none of the 62 men who had the treatment experienced erectile dysfunction or urinary incontinence.
Diffusion-weighted technique found to have a sensitivity and specificity of 89%-91% and 77%-81%, respectively.
At 5 years after seed implantation, 59% prostate cancer patients had preserved erectile function.
In a study, the 12-year prostate cancer survival rate was 61.8% for men with the mutation versus 94.3% for those without it.
Urinary levels of a melatonin metabolite below the median were associated with a 4-fold increased risk versus levels above the median.
Increased absolute effect at 13 years compared with findings at nine and 11 years.
It is more sensitive than digital rectal examination and transrectal ultrasound and more specific than PSA and PSA density, researchers report.
A questionnaire-based study revealed significant side effects that are not commonly discussed.
Reduced likelihood of biochemical recurrence of prostate cancer also linked to concomitant hormonal therapy and positive surgical margins.
As body mass index increases, so does the risk of kidney and bladder cancers in men and stomach, ovarian, and colon cancers in women.
Epigenetic assay has a high negative predictive value for prostate cancer.
Study reveals a 2-fold greater likelihood of primary kidney and bladder cancer compared with men in the general population.
Patients with substance use disorder are more likely to be hospitalized and to make emergency department visits.